VEGFA and cancer: In addition, the other successful agents applied in cancer targeting include anti-VEGF mAb bevacizumab (Avastin); the Fab fragment ranibizumab (Lucentis), approved in 2004 and 2006, respectively; and the humanized rabbit anti-VEGF monoclonal antibody BD0801 in phase III clinical developmental stage.